EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: A case of carbapenem hypersensitivity and tigecycline-associated coagulopathy after immunotherapy for advanced oral cancer

Yifei Peng, Rui Peng

Frontiers in Medicine · 30.06.2026 · 13

DOI: 10.3389/fmed.2026.1863232 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 30.06.2026. Verfasst von Yifei Peng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Traditional Chinese Medicine, Leshan, Sichuan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Managing complex infections after immunotherapy in patients with advanced head and neck cancer is clinically challenging, especially when severe adverse drug reactions like carbapenem hypersensitivity and tigecycline-associated coagulopathy further limit treatment options. This case demonstrates the potential contribution of clinical pharmacists in such difficult scenarios. Case presentation A 74-year-old man with oral squamous cell carcinoma developed severe sepsis after one cycle of PD-1 inhibitor (penpulimab) plus EGFR inhibitor (cetuximab). The clinical pharmacist sequentially recommended escalation to meropenem, switch to piperacillin-tazobactam, and addition of vancomycin. Later, the pharmacist recognized possible imipenem-related central nervous system effects, leading to discontinuation of all carbapenems due to possible cross-hypersensitivity. Subsequently, tigecycline was initiated, its associated coagulopathy was managed, and a switch to doxycycline was made.

Results

The patient’s fever resolved, and coagulation substantially improved; the infection was finally controlled. Causality was assessed using the Naranjo scale (imipenem 7, meropenem 5) and the RUCAM scale (penpulimab 6).

Conclusion

In this case, the clinical pharmacist’s dynamic assessment and use of quantitative adverse reaction tools (Naranjo and RUCAM scales) contributed to successful infection control and management of drug toxicity.

Schlagwörter

Stichwörter der Autor:innen

carbapenem allergyclinical pharmacistcoagulopathyimmunotherapyoral squamous cell carcinomasepsistigecycline

Autor:innen und Institutionen

  • Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Traditional Chinese Medicine, Leshan, Sichuan, China.

Zitieren

APA

Peng, Y., & Peng, R. (2026). Case Report: A case of carbapenem hypersensitivity and tigecycline-associated coagulopathy after immunotherapy for advanced oral cancer. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1863232

Vancouver

Peng Y, Peng R. Case Report: A case of carbapenem hypersensitivity and tigecycline-associated coagulopathy after immunotherapy for advanced oral cancer. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1863232

BibTeX
@article{Peng2026,
  author = {Peng, Yifei and Peng, Rui},
  title = {Case Report: A case of carbapenem hypersensitivity and tigecycline-associated coagulopathy after immunotherapy for advanced oral cancer},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1863232}
}
Kostenlos starten →